储存条件对沙特阿拉伯市售甲硝唑商用片剂溶解性能的影响

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Saudi Pharmaceutical Journal Pub Date : 2024-06-12 DOI:10.1016/j.jsps.2024.102134
Basmah N. Aldosari, Areej M. Al-Mutairi, Alanood S. Almurshedi, Iman M. Alfagih, Bushra T. Al Quadeib, Eram Eltahir, Salma S. Almarshidy, Mohamed A. Ibrahim, Amal El Sayeh F. Abou El Ela
{"title":"储存条件对沙特阿拉伯市售甲硝唑商用片剂溶解性能的影响","authors":"Basmah N. Aldosari,&nbsp;Areej M. Al-Mutairi,&nbsp;Alanood S. Almurshedi,&nbsp;Iman M. Alfagih,&nbsp;Bushra T. Al Quadeib,&nbsp;Eram Eltahir,&nbsp;Salma S. Almarshidy,&nbsp;Mohamed A. Ibrahim,&nbsp;Amal El Sayeh F. Abou El Ela","doi":"10.1016/j.jsps.2024.102134","DOIUrl":null,"url":null,"abstract":"<div><p>This study aimed to investigate the impact of storage conditions on the dissolution performance of commercial metronidazole (MTZ) tablets available in Saudi Arabia; these were coded as the reference and Test A, Test B, and Test C products. Moreover, the hardness and the disintegration time were measured. The UV spectrophotometrically analytical technique was utilized to quantify MTZ. All the control tablets, which were tested upon receipt, met the USP requirement as not less than 85 % of the labeled amount of MTZ was dissolved in 60 min. The MTZ reference released 91.79 % ± 1.23 after 60 min, while the products A, B, and C released 87.96 % ± 2.60, 93.26 % ± 2.01, and 88.61 % ± 2.04, respectively. The different dissolution parameters calculated for all the control tablets showed that the MTZ products A and B had optimal dissolution performances and were considered similar to the reference product. The product C showed a significantly reduced dissolution performance and was considered different from the reference. The in vitro dissolution of the MTZ tablets stored at 40oC ± 2 oC/75 % RH ± 5 % for 6 months indicated that the tablets maintained compliance with the USP requirement. The MTZ reference released 89.36 % ± 3.64 after 60 min, while the products A, B, and C released 95.79 % ± 3.91, 88.52 % ± 2.52, and 87.79 % ± 5.04, respectively. However, a slight reduction in the percentage released after 30 min (% DE30) and a slight increase in the mean dissolution time (MDT) were observed during the first 3 months of storage under stressed conditions. These changes were more obvious after 6 months of storage under the same conditions. Furthermore, in vitro dissolution of the product C stored at 40oC ± 2 oC/75 % RH ± 5 % for 3 months with further protection against high humidity revealed an improvement in the dissolution parameters due to the similar protective effects exerted by the two packaging forms. Furthermore, the study shows that storage conditions such as humidity and temperature affect in vitro dissolution of MTZ marketed tablets which may have an impact on efficiency and patient safety.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 8","pages":"Article 102134"},"PeriodicalIF":3.0000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001841/pdfft?md5=cc653970d673cc732dc29b0b01582191&pid=1-s2.0-S1319016424001841-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Impacts of storage conditions on the dissolution performance of commercial metronidazole tablets available in Saudi Arabia\",\"authors\":\"Basmah N. Aldosari,&nbsp;Areej M. Al-Mutairi,&nbsp;Alanood S. Almurshedi,&nbsp;Iman M. Alfagih,&nbsp;Bushra T. Al Quadeib,&nbsp;Eram Eltahir,&nbsp;Salma S. Almarshidy,&nbsp;Mohamed A. Ibrahim,&nbsp;Amal El Sayeh F. Abou El Ela\",\"doi\":\"10.1016/j.jsps.2024.102134\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This study aimed to investigate the impact of storage conditions on the dissolution performance of commercial metronidazole (MTZ) tablets available in Saudi Arabia; these were coded as the reference and Test A, Test B, and Test C products. Moreover, the hardness and the disintegration time were measured. The UV spectrophotometrically analytical technique was utilized to quantify MTZ. All the control tablets, which were tested upon receipt, met the USP requirement as not less than 85 % of the labeled amount of MTZ was dissolved in 60 min. The MTZ reference released 91.79 % ± 1.23 after 60 min, while the products A, B, and C released 87.96 % ± 2.60, 93.26 % ± 2.01, and 88.61 % ± 2.04, respectively. The different dissolution parameters calculated for all the control tablets showed that the MTZ products A and B had optimal dissolution performances and were considered similar to the reference product. The product C showed a significantly reduced dissolution performance and was considered different from the reference. The in vitro dissolution of the MTZ tablets stored at 40oC ± 2 oC/75 % RH ± 5 % for 6 months indicated that the tablets maintained compliance with the USP requirement. The MTZ reference released 89.36 % ± 3.64 after 60 min, while the products A, B, and C released 95.79 % ± 3.91, 88.52 % ± 2.52, and 87.79 % ± 5.04, respectively. However, a slight reduction in the percentage released after 30 min (% DE30) and a slight increase in the mean dissolution time (MDT) were observed during the first 3 months of storage under stressed conditions. These changes were more obvious after 6 months of storage under the same conditions. Furthermore, in vitro dissolution of the product C stored at 40oC ± 2 oC/75 % RH ± 5 % for 3 months with further protection against high humidity revealed an improvement in the dissolution parameters due to the similar protective effects exerted by the two packaging forms. Furthermore, the study shows that storage conditions such as humidity and temperature affect in vitro dissolution of MTZ marketed tablets which may have an impact on efficiency and patient safety.</p></div>\",\"PeriodicalId\":49257,\"journal\":{\"name\":\"Saudi Pharmaceutical Journal\",\"volume\":\"32 8\",\"pages\":\"Article 102134\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1319016424001841/pdfft?md5=cc653970d673cc732dc29b0b01582191&pid=1-s2.0-S1319016424001841-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Saudi Pharmaceutical Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1319016424001841\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Pharmaceutical Journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1319016424001841","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

本研究旨在调查贮藏条件对沙特阿拉伯市售甲硝唑(MTZ)商用片剂溶出性能的影响;这些片剂被编码为参考产品、试验 A、试验 B 和试验 C 产品。此外,还测量了硬度和崩解时间。采用紫外分光光度分析技术对 MTZ 进行定量。所有对照药片在收到后都进行了测试,符合美国药典的要求,即在 60 分钟内溶解的 MTZ 含量不少于标签量的 85%。60 分钟后,MTZ 参考品释放了 91.79 % ± 1.23%,而产品 A、B 和 C 分别释放了 87.96 % ± 2.60%、93.26 % ± 2.01% 和 88.61 % ± 2.04%。对所有对照药片计算的不同溶出度参数表明,MTZ 产品 A 和 B 具有最佳的溶出性能,与参比产品相似。产品 C 的溶出性能明显降低,被认为与参比产品不同。MTZ 片剂在 40oC ± 2 oC/75 % RH ± 5 % 的条件下储存 6 个月的体外溶出度表明,这些片剂始终符合美国药典的要求。60 分钟后,MTZ 参考品释放出 89.36 % ± 3.64%,而产品 A、B 和 C 分别释放出 95.79 % ± 3.91%、88.52 % ± 2.52% 和 87.79 % ± 5.04%。不过,在受压条件下储存的前 3 个月,观察到 30 分钟后释放的百分比(DE30%)略有下降,平均溶解时间(MDT)略有增加。在相同条件下储存 6 个月后,这些变化更加明显。此外,将产品 C 在 40oC ± 2 oC/75 % RH ± 5 % 的条件下存放 3 个月,并进一步防止高湿度,体外溶出度显示,由于两种包装形式具有类似的保护作用,溶出度参数有所改善。此外,该研究还表明,湿度和温度等储存条件会影响 MTZ 上市片剂的体外溶出度,这可能会影响效率和患者安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Impacts of storage conditions on the dissolution performance of commercial metronidazole tablets available in Saudi Arabia

This study aimed to investigate the impact of storage conditions on the dissolution performance of commercial metronidazole (MTZ) tablets available in Saudi Arabia; these were coded as the reference and Test A, Test B, and Test C products. Moreover, the hardness and the disintegration time were measured. The UV spectrophotometrically analytical technique was utilized to quantify MTZ. All the control tablets, which were tested upon receipt, met the USP requirement as not less than 85 % of the labeled amount of MTZ was dissolved in 60 min. The MTZ reference released 91.79 % ± 1.23 after 60 min, while the products A, B, and C released 87.96 % ± 2.60, 93.26 % ± 2.01, and 88.61 % ± 2.04, respectively. The different dissolution parameters calculated for all the control tablets showed that the MTZ products A and B had optimal dissolution performances and were considered similar to the reference product. The product C showed a significantly reduced dissolution performance and was considered different from the reference. The in vitro dissolution of the MTZ tablets stored at 40oC ± 2 oC/75 % RH ± 5 % for 6 months indicated that the tablets maintained compliance with the USP requirement. The MTZ reference released 89.36 % ± 3.64 after 60 min, while the products A, B, and C released 95.79 % ± 3.91, 88.52 % ± 2.52, and 87.79 % ± 5.04, respectively. However, a slight reduction in the percentage released after 30 min (% DE30) and a slight increase in the mean dissolution time (MDT) were observed during the first 3 months of storage under stressed conditions. These changes were more obvious after 6 months of storage under the same conditions. Furthermore, in vitro dissolution of the product C stored at 40oC ± 2 oC/75 % RH ± 5 % for 3 months with further protection against high humidity revealed an improvement in the dissolution parameters due to the similar protective effects exerted by the two packaging forms. Furthermore, the study shows that storage conditions such as humidity and temperature affect in vitro dissolution of MTZ marketed tablets which may have an impact on efficiency and patient safety.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Saudi Pharmaceutical Journal
Saudi Pharmaceutical Journal PHARMACOLOGY & PHARMACY-
CiteScore
6.10
自引率
2.40%
发文量
194
审稿时长
67 days
期刊介绍: The Saudi Pharmaceutical Journal (SPJ) is the official journal of the Saudi Pharmaceutical Society (SPS) publishing high quality clinically oriented submissions which encompass the various disciplines of pharmaceutical sciences and related subjects. SPJ publishes 8 issues per year by the Saudi Pharmaceutical Society, with the cooperation of the College of Pharmacy, King Saud University.
期刊最新文献
Drug delivery for age-related bone diseases: From therapeutic targets to common and emerging therapeutic strategies Impacts of Anabolic-androgenic steroid supplementation on female health and offspring: Mechanisms, side effects, and medical perspectives Bioadhesive hybrid system of niosomes and pH sensitive in situ gel for itraconazole ocular delivery: Dual approach for efficient treatment of fungal infections Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1